Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19
March 27, 2020 13:48 ET
|
Altasciences Company Inc.
LAVAL, Quebec, March 27, 2020 (GLOBE NEWSWIRE) -- Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage...
WPD Pharmaceuticals Provides 2019 Corporate Year End Review
January 08, 2020 03:05 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Westcot Ventures Corp. (CSE: WBIO) (the “Company”), and its wholly-owned subsidiary WPD Pharmaceuticals sp. z.o.o (“WPD”), a clinical...
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
June 04, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe
May 09, 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
October 03, 2018 01:00 ET
|
ObsEva SA
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission...
Celixir announces US FDA approval of the IND application for cell therapy Heartcel
June 08, 2018 02:00 ET
|
CELIXIR Plc
Celixir announces US FDA approval of the IND application for cell therapy HeartcelTM FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250...
3D Signatures Inc. Announces Closing of Second Tranche of Brokered Private Placement
December 22, 2016 16:38 ET
|
3D Signatures Inc
WINNIPEG, MB--(Marketwired - December 22, 2016) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or...
3D Signatures Appoints Two Industry Specialists to Board Positions
December 09, 2016 07:00 ET
|
3D Signatures Inc.
WINNIPEG, MB--(Marketwired - December 09, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3DS") is pleased to announce two additional strategic appointments to its Board of Directors...
Are You Ready to Be An Expert Witness?
April 14, 2010 11:17 ET
|
Author Judd Robbins
ASHLAND, OR--(Marketwire - April 14, 2010) - Judd Robbins did not get into computers to become an expert witness.
He has advanced degrees from UC Berkeley and the University of Michigan,...
XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid Arthritis
March 04, 2009 08:00 ET
|
XOMA Corporation
BERKELEY, Calif., March 4, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced the initiation of a Phase 2a clinical study evaluating its product candidate XOMA 052, a potent monoclonal...